We aimed to assess the association of changes in brachial or central nocturnal systolic blood pressure (SBP) with change in urine albumin-creatinine ratio (UACR) by a valsartan/amlodipine combination (80/5 mg) therapy in hypertensive patients.
Noninvasive measurements of central (aortic) blood pressure (BP) with arterial tonometry, 1 reflecting the pressure experienced by perfused target organs (e.g., the brain and kidneys), have stronger associations with cardiovascular end-organ target organ damage and incident cardiovascular disease compared with brachial BP measurements. 2, 3 The central BP may also be associated with kidney dysfunction 4, 5 because the kidneys have a torrential circulation with low vascular resistance and receive high flow at a short distance from the aorta. 6, 7 Given that the kidney tends to be exposed to higher blood flow during sleep than in the daytime, 8, 9 a reduction of central nocturnal BP may be associated with renal protection.
Previous studies have demonstrated that a reduction of brachial nocturnal BP as assessed by ambulatory BP monitoring (ABPM) was associated with a reduction of the urinary albumin-creatinine ratio (UACR). 10 However, whether a reduction of central nocturnal BP is associated with a reduction of UACR, independently of brachial nocturnal BP change, is unknown.
Using data from the ChronotheraPy for ambulatory cEnTral pressure (CPET) study, in which valsartan/amlodipine combination therapy was administered to hypertensive patients over 16 weeks, we tested our hypothesis that a reduction in central nocturnal BP would be associated with a reduction of UACR and that this association would be independent of the reduction of brachial nocturnal BP, as a substudy of the CPET study.
METHODS

Study design
The details of the CPET study have been published previously. 11 Briefly, eligible patients were randomized in a blind fashion to receive 1 of 2 treatments: morning or bedtime administration of a fixed-dose valsartan/amlodipine (80/5 mg) combination tablet, which is the standard dose for Japanese, over 8 weeks (the first period). Over the next 8 weeks (the second period), all patients were switched to receive the other treatment (Supplementary Figure S1) . We verified the basic assumptions of cross-over design, by excluding drug-order effects (morning/bedtime administration or bedtime/morning administration) and period effects (the first 8-week period or the second 8-week period), using a linear mixed model analysis. The primary end points were similar between the morning and bedtime administration groups, 11 and therefore, analyses were conducted by merging all participant data in this subanalysis of the CPET study.
BP measurements
Ambulatory BP. Oscillometric ABPM that records both brachial and central BP was obtained using a Mobil-OGraph NG (IEM, Stolberg, Germany). This device estimates central BP noninvasively using the ARCSolver algorithm. 12 In this algorithm, the central aortic pressures are estimated based on brachial pulse wave data using a generalized transfer function. 12 The ARCSolver algorithm-derived central BP values are comparable with central BP measurements obtained in an invasive manner. 12 Patients underwent 24-hour ABPM at baseline and 16 weeks later. Ambulatory BP readings were taken at 30-minute intervals throughout a 24-hour period. The data from the ABPM were automatically stored in the memory of the device and transferred electronically to personal computers equipped with IEM software for analyzing the obtained data.
Nocturnal BP was defined as the average BP values over the period from when patients went to bed until they woke in the morning. Daytime BP was defined as the average BP for the rest of the day.
Clinic BP. Clinic BP was measured using a validated cuff oscillometric device (HEM-907; Omron Healthcare, Kyoto, Japan) according to the Japanese Society of Hypertension 2014 guideline. 13 Briefly, clinic BP was measured after patients had rested for at least 2 minutes in a seated position with the legs not crossed, in a quiet environment. Two consecutive measurements were taken at a 1-to 2-minute interval, and their average was used to define clinic BP.
Blood and urine examinations
Fasting blood and spot urine samples were collected from all patients at baseline and the end of the intervention. All samples were sent to a single laboratory (SRL Inc., Tokyo) within 24 hours after collection. Urinary albumin excretion was measured using an immunoturbidity kit (AutoWako Microalbumin; Wako Pure Chemical Industries, Ltd., Osaka, Japan) and was expressed as a creatinine ratio (UACR) (mg/g·Cr). The intra-assay and interassay coefficients of UACR were <5%.
Chronic kidney disease (CKD) was defined as a serum creatinine-based estimated glomerular filtration rate (eGFRcreat) <60 ml/min/1.73 m 2 and/or microalbuminuria, a UACR ≥30 mg/g·Cr. 14 We used the CKD-EPI equation when calculating eGFRcreat as follows: eGFRcreat = 141 × min (Scr/κ, 1) α × max (Scr/κ, 1) −1.209 × 0.993 Age × 1.018 [if women], where Scr is serum creatinine, κ is 0.7 for women and 0.9 for men, α is −0.329 for women and −0.411 for men, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. 15, 16 Diabetes mellitus was defined as a fasting glucose level of ≥126 mg/dl and/or a casual glucose level of ≥200 mg/dl or treated diabetes.
Statistical analyses
Descriptive statistics are presented as the means and SD or proportions where appropriate. UACR was natural logtransformed before analyses because of the skewed distributions. The differences in BP, heart rate (HR), and natural log-transformed UACR obtained at baseline vs. 16 weeks later were compared using paired t-test. Univariate correlations were evaluated as Pearson correlation coefficients. Multivariate regression analyses were performed to compare the associations of changes in brachial nocturnal systolic blood pressure (SBP) vs. central nocturnal SBP with change in UACR by intervention. Additionally, in subanalyses, the association between changes in brachial nocturnal pulse pressure (PP) vs. central nocturnal PP and change in UACR was assessed. Covariates included age, gender, clinical characteristics at baseline (body mass index, smoking status, habitual drinking, prevalent diabetes mellitus, and baseline total cholesterol) and change in nocturnal HR on ABPM. These covariates have been shown to be correlated with BP and UACR. 17, 18 To identify multicollinearity, we assessed the variation inflation factor. Variation inflation factor values >10 were considered to indicate multicollinearity. Statistical analyses were performed using SPSS version 24.0 (SPSS, Chicago, IL). A P value <0.05 was considered significant.
RESULTS
Baseline characteristics
Twenty-three patients completed the intervention over 16 weeks. Table 1 provides demographic variables and clinical characteristics of the included patients. Of the 23 patients, 15 (65%) were women; the mean (SD) age was 68.0 (8.7) years, and 65% had CKD. Figure 1 shows changes in eGFRcreat and UACR by intervention.
Changes in UACR and BP by intervention
All ambulatory BP parameters, including brachial and central measurements, were significantly reduced by intervention (Table 2) .
In univariate analyses, reductions in brachial nocturnal SBP (r = 0.445, P = 0.033) and central nocturnal SBP (r = 0.616, P = 0.002) by intervention were associated with a reduction in UACR, respectively (Table 3 ). In multivariate regression analyses including brachial nocturnal SBP and central nocturnal SBP jointly, only central nocturnal SBP change was associated with a reduction in UACR (β = 0.919, P = 0.020) (Table 4) .
Additionally, in subanalyses, changes in brachial and central nocturnal PP were associated with change in UACR over 16 weeks (Supplementary Table S1 ). When change in brachial nocturnal PP and change in central nocturnal PP were analyzed jointly, only central nocturnal PP change was associated with a reduction in UACR (Supplementary Table S2 ).
Brachial and central SBP, brachial and central DBP, and UACR were reduced from baseline to 8 weeks (Supplementary  Table S3 and Figure S2 ). Changes in nocturnal brachial or central SBP were not associated with change in UACR over 8 weeks (Supplementary Tables S4 and S5 ).
DISCUSSION
The main findings of this CPET substudy were as follows: (i) the central nocturnal SBP change was significantly associated with reduction in UACR and (ii) the association between the central nocturnal SBP change and reduction in UACR was independent of the brachial nocturnal SBP change. To the best of our knowledge, this is the first study showing that central nocturnal SBP change is closely associated with renal protection, independently of brachial nocturnal SBP change.
In the present study, we demonstrated that reduction in UACR was significantly associated with central nocturnal SBP change, independently of brachial nocturnal SBP change. Our results indicated that there might be a special relationship between UACR and central nocturnal SBP. In the kidneys, aortic pulsations might extend more deeply toward the fragile glomerular capillaries, 19 and increased aortic pulsation would induce renal vulnerable microvasculature damage, 20 which could lead to microalbuminuria, an early marker of vascular damage. In addition, the renal blood flow might increase during bedtime due to the increase of venous filling. Moreover, microcirculation of the kidneys has been reported to change markedly with aging. 19 The central PP is widened by large arterial stiffening, which would cause high BP pulsation to the glomerular capillaries. 21 We speculated that these might be reasons why central nocturnal SBP change was associated with a reduction in UACR, independently of brachial nocturnal SBP in this study. In addition, we confirmed that the change in central nocturnal PP played an important role in the reduction in UACR. Our results might indicate that reduction in central nocturnal BP would be a therapeutic target to protect the kidneys.
The valsartan/amlodipine combination showed significant reduction of central BP throughout a 24-hour period. In a previous study, a renin-angiotensin-aldosterone system (RAAS) inhibitor/CCB combination showed greater Data are the mean ± SD or number (percentage). Chronic kidney disease was defined as eGFRcreat <60 ml/min/1.73 m 2 or albuminuria UACR ≥30 mg/g·Cr. Abbreviations: ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFRcreat, creatinine-based estimated glomerular filtration rate; HR, heart rate; SBP, systolic blood pressure; UACR, urinary albumin-creatinine ratio. Data are the mean ± SD. P values were calculated by paired t-test. Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.
reductions of central SBP compared with a RAAS inhibitor/ diuretic combination, despite the lack of a significant difference in brachial SBP reduction in the Japan Combined treatment with Olmesartan and a CCB vs. olmesartan and diuretics Randomized Efficacy (J-CORE) study. 22 Several reports also indicated that the RAAS inhibitor/CCB combination is more effective at lowering central BP than other antihypertensive combinations. In the Conduit Artery Function Evaluation (CAFE) study, a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), atenolol ± thiazide-based treatment was much less effective than amlodipine ± perindopril-based treatment at lowering central BP despite the insignificant difference in brachial BP. 23 The Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension with Amlodipine 5 mg (EXPLOR) study showed that an amlodipine/valsartan combination significantly decreased central SBP more than an amlodipine/atenolol combination, despite the similar change in brachial SBP. 24 Angiotensin II blockade is associated with reverse remodeling of small and large arteries, which leads to a significant and selective reduction of central PP and arterial stiffness. 25 CCB causes a powerful arteriolar vasodilation, reduction of pressure wave reflections, 22 and regression of arteriolar hypertrophy. 26 These results indicated that the combination of RAAS inhibitor and CCB would be more appropriate than other antihypertensive combinations for lowering central BP levels.
With respect to the renal protective effects, the RAAS inhibitor/CCB combination showed a significantly better effect on maintenance of the eGFRcreat/creatinine clearance and significantly better reduction of serum creatinine, 27 and both these actions led to a more effective reduction in the progression of CKD 28 compared with the RAAS inhibitor/ diuretic combination. In addition, previous studies demonstrated that the RAAS inhibitor/CCB combination could reduce UACR significantly from baseline. 29, 30 Taking these results into account, the RAAS inhibitor/CCB combination might have a better renal protective effect through the changes in renal hemodynamics than the RAAS inhibitor/ diuretic combination.
There are some limitations of this study. First, the number of patients (n = 23) was small. Second, 65% of this study population had CKD at baseline. Patients with CKD are known to have a high incidence of nocturnal hypertension. 31 In addition, it is possible that the baseline eGFRcreat might affect reduction in UACR. Although a subgroup analysis could exclude this factor, we were unable to perform such an analysis due to the small sample size. Third, the mean age of the patients in this study was 68.0 years. Whether similar results would have been seen in much younger patients is unknown and merits further investigation. Fourth, it was not clear whether this novel device, the Mobil-O-Graph NG, provided a realistic estimation of accurate central nocturnal BP values. However, central BP as obtained with the Mobil-O-Graph NG was previously reported to show good agreement with the validated tonometry method (SphygmoCor) in the supine position. 12 Finally, the suggested close association between central nocturnal SBP change and reduction in UACR must be confirmed by large-scale interventional studies.
CONCLUSION
Central nocturnal SBP change was significantly associated with a reduction in the UACR, independently of brachial Each multivariate regression model was adjusted for age, gender, clinical characteristics at baseline (body mass index, smoking status, habitual drinking, prevalent diabetes mellitus, and baseline total cholesterol) and change in nocturnal HR on ABPM. P values were calculated by multiple regression analyses. Abbreviations: β, standardized regression coefficient; R 2 , multiple coefficient of determination; SBP, systolic blood pressure; UACR, urinary albumin-creatinine ratio; VIF, variance inflation factor.
nocturnal SBP change, induced by a valsartan/amlodipine combination therapy. Central nocturnal SBP may be a therapeutic target for protection of the kidney. A large-scale interventional study is needed to investigate whether central nocturnal SBP change confers kidney protection through a reduction in the UACR.
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Supplementary data are available at American Journal of Hypertension online.
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